

GenScript Vector-based siRNA Protocol (CMV Promoter)



Technical Manual No. 0172

Version 04032007

I	Introduction	1
II	Vector-based siRNA	1
III	siRNA Expression Vector Using CMV Promoter	2
IV	Product description	4
V	Cloning siRNA insert into GenScript pRNA vectors	5
VI	Transfecting mammalian cells	6
VII	Selecting antibiotic-resistant transfected cells	7
VIII	References	8

I. Introduction:

RNAi (RNA interference) is a phenomenon that small double-stranded RNA (referred as small interfering RNA or siRNA) can knock down the expression of its corresponding gene. RNAi has been observed in plants, *C.elegans* and *Drosophila* long time ago. It was until recently that RNAi was discovered to work in mammalian system [1].

Small interfering RNA (siRNA) is 19-22 nt double-stranded RNA. It works by cleaving and destroying its cognate RNA. siRNA first assembles into RNA-induced silencing complexes (RISCs), where it then activates the complex by unwinding its RNA strands. The unwound RNA strands subsequently guide the complex to the complementary RNA molecules, where the complex cleaves and destroys the cognate RNA, which results in RNAi phenomenon. RNAi has evolved into a powerful tool to study gene functions and it also has potential applications in gene therapy.

II. Vector-based siRNA

Using DNA vector-based siRNA technology, a small DNA insert (about 70 bp) encoding a short hairpin RNA targeting the gene of interest is cloned into a commercially available vector. The insert-containing vector can be transfected into the cell, and it expresses the short hairpin RNA. The hairpin RNA is rapidly processed by the cellular machinery into 19-22 nt double stranded RNA (siRNA).

Key features of vector-based siRNA:

1. **More stable and easier to handle:** Vector-based siRNA is delivered as plasmids, which is more stable and easier to handle than synthetic siRNA.
2. **Stable cell line can be established:** Vector based siRNA allows you to obtain a stable cell line, and observe long-term effects of RNAi [2-5].
3. **Viral siRNA can be prepared [6,7]:** Viral siRNA can be used to infect primary cell lines and used for gene therapy purpose.
4. **Inducible system can be established:** Vector based siRNA allows you to establish an inducible system by using a vector with an inducible promoter.
5. **A knock-out mouse line can be established using transgenic siRNA method [8].**
6. **Unlimited supply:** once a DNA construct is made, you will have unlimited supply of siRNA.



It is recommended that at least 3 vector-based siRNA should be prepared for each gene to find the most potent and most specific siRNA. Here are the reasons:

1. **Not all siRNA target sequences are equally potent:** Because of secondary structure and other factors, some target sequences are more potent than others. It is better to test at least three vector-siRNA constructs to find the most potent one.
2. **Not all siRNA silencing effects are gene-specific:** It has been reported that some siRNA silencing effects are not gene-specific because of various reasons. It is better to validate your experiments results using three vector-based siRNA constructs.
3. **Results from synthetic siRNA or siRNA cassette cannot be completely transferred to vector-based siRNA construct:** Vector-based siRNA is different from synthetic siRNA oligos or siRNA cassette. Although the results from synthetic siRNA oligos or siRNA cassette can suggest the most potent siRNA targets, the results cannot be completely duplicated in vector-based siRNA for unknown reasons.
4. **The experiment is still the gold test stone:** Although we are proud of our vector-based siRNA design program, the best design is still not as good as what the experiments can tell you.

III. siRNA Expression Vector Using CMV Promoter

Human cytomegalovirus (CMV) promoter is one of the strongest promoters described. Based on RNA polymerase II system, CMV promoter drives higher-level constitutive expression of genes in a broader variety of mammalian cell lines, compared with RNA polymerase III based promoters such as U6 and H1. Also with CMV promoter, siRNA gets long-term expression and silences the target gene accordingly. GenScript has designed and constructed a series of siRNA expression vectors using CMV promoter to drive siRNA expression. These vectors are validated and some results are shown in Figure 3.

In pRNA-CMV3.1 series vectors, pRNA-CMV3.1-Neo (SD1231), pRNA-CMV3.1-Hygro (SD1232), and pRNA-CMV3.1-Puro (SD1233), CMV promoter drives the expression of siRNA, and SV40 promoter drives resistance genes. siRNA cassettes can be easily inserted into the vectors between BamH I and Hind III sites. The circle map of pRNA-CMV3.1-Neo (SD1231) is shown in Figure 1. Other two vectors (SD1232 and SD1233) have the similar maps except the resistance genes.




Figure 1. Circle map of pRNA-CMV3.1-Neo (SD1231)

In pRNAT-CMV3.1 series vectors, pRNAT-CMV3.1-Neo (SD1261), pRNAT-CMV3.1-Hygro (SD1262), and pRNAT-CMV3.1-Puro (SD1263), cGFP (coral GFP) was cloned under SV40 promoter to track transfection efficiency. SV40 promoter drives both cGFP and resistance genes using an internal ribosome entry site (IRES). siRNA cassettes can be inserted into the vectors between BamH I and Afl II sites. The circle map of pRNAT-CMV3.1-Neo (SD1261) is shown in Figure 2. Other two vectors (SD1262 and SD1263) have the similar maps except the resistance genes.




Figure 2. Circle map of pRNAT-CMV3.1-Neo (SD1261)

pRNAT-CMV3.2 series vectors, pRNAT-CMV3.2-Neo (SD1264), pRNAT-CMV3.1-Hygro (SD1265), and pRNAT-CMV3.1-Puro (SD1266), were constructed in the similar way as pRNAT-CMV3.1 series vectors except that Afl II site was replaced by Xho I site to increase cloning efficiency. siRNA cassettes can be easily inserted into the vectors between BamH I and Xho I sites. The circle map of pRNAT-CMV3.2-Neo (SD1264) is shown in Figure 3. Other two vectors (SD1265 and SD1266) have the similar maps except the resistance genes.




Figure 3. Circle map of pRNAT-CMV3.2-Neo (SD1264)





Figure 4. Effect of siFluc on Firefly Luciferase. All the activities are normalized by Renilla Luciferase activity.

The activities are from:

- Control: HEK293 cells transfected with pGL3-control (0.16 μ g) and pRL-TK (0.16 μ g), and 1.6 μ g of pUC18.
- U6-siFLuc: HEK293 cells transfected with pGL3-control (0.16 μ g), pRL-TK (0.16 μ g), and 1.6 μ g of pRNA-U6-Neo-siFLuc (Cat. SD1501).
- CMV3.1-siFLuc: HEK293 cells transfected with pGL3-control (0.16 μ g), pRL-TK (0.16 μ g), and 1.6 μ g of pRNA-CMV3.1-Neo-siFLuc (Cat. SD1531).
- U6-empty: HEK293 cells transfected with pGL3-control (0.16 μ g), pRL-TK (0.16 μ g), and 1.6 μ g of pRNA-U6.1/Neo vector (Cat. SD1201).

IV. Product Description

Description: A small DNA insert (about 70-80 bp) encoding a short hairpin RNA targeting the gene of interest is cloned into a siRNA expression vector. The insert-containing vector can be transfected into the cell, and expresses the short hairpin RNA.



Cloning sites: *BamH* I and *Hind* III for pRNA-CMV3.1.

BamH I and *Afl* II for pRNAT-CMV3.1

BamH I and *Xho* I for pRNAT-CMV3.2

- Promoter: Cytomegalomaavirus (CMV) promoter for siRNA expression.
- Vector resistance: Options include neomycin, hygromycin, and puromycin.
- pRNAT-CMV3.1 and pRNAT-CMV3.2 series vectors also contain cGFP marker.



Quantity: 10 µg.

Quality Control: The promoter and cloning sites are sequencing verified.

Storage: -20 °C after receiving.

Positive Controls:

Target Gene	Firefly Luciferase	
Cat. No.	SD1531	SD1532
Resistance	Neomycin	Hygromycin

siRNA Expression Vectors Using CMV Promoter:

Cat. No.	SD1231	SD1232	SD1233
Promoter	CMV	CMV	CMV
Resistance	Neomycin	Hygromycin	Puromycin

siRNA Expression Vectors with cGFP marker:

Cat. No.	SD1261 SD1264	SD1262 SD1265	SD1263 SD1266
Promoter	CMV	CMV	CMV
Resistance	Neomycin	Hygromycin	Puromycin
Marker	cGFP	cGFP	cGFP

V. Cloning siRNA insert into GenScript pRNA vectors.

1. siRNA Design: GenScript has developed a proprietary algorithm for designing a siRNA target and building the insert. To find the target sequence and build siRNA insert, please use GenScript's siRNA design center siRNA Target Finder and siRNA Construct Builder (<http://www.genscript.com/rnai.html>).
2. Custom vector-based siRNA constructs: GenScript provides custom vector-based siRNA at a very competitive price. Alternatively, you can use the following protocol to make the vector-based siRNA constructs yourself.
3. Order two oligos with cohesive *Bam*H I and *Hind* III sites (or *Bam*H I and *Afl* II sites for pRNAT-CMV3.1 series vectors, or *Bam*H I and *Xho* I sites for pRNAT-CMV3.2 series vectors). The oligos must be PAGE purified oligos. Dissolve the oligos in water to 1 µg/µl concentration.
4. Anneal the two oligos. Prepare a 20 µl annealing reaction in the following way:
 - 1 µl top-strand oligo
 - 1 µl bottom-strand oligo
 - 1 µl 20 x SSC (Sigma, Cat. S6639)
 - 17 µl water
5. Heat the mixture at 95 °C for 10 min. Take it out and leave it at room temperature for one hour. Dilute the mixture to a final insert concentration of 40 ng/µl with 30 µl of TE buffer .
6. Cut the vector with *Bam*H I and *Hind* III (or *Xho* I or *Afl* II). Run a 1% agarose gel and purify the vector.
7. Ligate the vector with the insert using T4 ligase (the molar ratio of insert to vector is 3:1). **For ligation with the ends produced by *Afl* II, use concentrated T4 ligase. For a 10 µl of ligation reaction, use 0.5 µl of 2,000 U/µl T4 DNA ligase from NEB (#M0202T or #M0202M) and incubate the reaction overnight at 16°C.**
8. Transform the ligation mixture into competent DH5a cells (Invitrogen, Cat. 18258-012). Plate it on LB-amp plates.
9. Choose at least 15 clones and grow them. Prepare MiniPreps from culture using GenScript MiniPrep kit.
10. Cut the plasmids with *Bam*H I and *Hind* III (or *Xho* I or *Afl* II). Run a 3% agarose gel to check whether the plasmids have the inserts and select positive clones.
11. Sequence the positive clones to verify the sequence of the insert.



VI. Transfecting mammalian cells.

Generate large amount of DNA:

Vector-based siRNA constructs are delivered as a lyophilized plasmid, and it can be stored forever at -20°C . You can handle the constructs in the same way as you handle DNA plasmid. Before use, add 20 μl water to dissolve it. Please vortex diligently and make sure the DNA is dissolved. If needed, incubate at 50°C for 10 min. You can use it directly if you only need less than 10 μg of DNA. For large amount of DNA, please take 1 or 2 μl of the solution and transform competent DH5a or TOP10 cells for a MaxiPrep using Qiagen MaxiPrep kit.

General considerations before transfection:

A variety of protocols such as lipofection and electroporation have been used successfully to transfect vector-based siRNA constructs into mammalian cells. The transfection procedures are identical to those used for DNA plasmid transfection. The choice of transfection procedures will depend on the mammalian cell line used. In general, we recommend using LipofectamineTM 2000 or LipofectaminTM Plus from Invitrogen. The information and protocol for LipofectamineTM 2000 can be found using this link: <http://www.lifetech.com/content.cfm?pageid=93>. The information and protocol for LipofectamineTM Plus can be found using this link: <http://www.invitrogen.com/content/sfs/manuals/18324.pdf>.

The following are important issues to be considered before performing the transfection:

- a. **Cell density:** The recommended cell density for transfection using LipofectamineTM 2000 is 90-95%. If the cell density is less than 90%, the LipofectamineTM 2000 may have some toxicity on the cells.
- b. **Vector-based siRNA construct amount:** For 12-well plates, it is recommended to use 1.6 μg as a starting point. To screen most potent siRNA target, it is recommended to use less DNA. For other plate size, the DNA amount can be adjusted proportionally.
- c. **Cell Proliferation:** Maintaining healthy cell culture is critical for cell transfection. It is essential to minimize decreased cell growth associated with nonspecific transfection effects.
- d. **Positive control and negative control:** It is always a good idea to include a positive and a negative control in the experiment. Since there is a lot of uncertainty in siRNA experiments, it is recommended to use a positive control to optimize your system. GenScript offers siFluc positive control. For negative control, you may use our online siRNA Scrambler Tool to design a specific negative control for your target sequence.
- e. **Time:** The optimal time after transfection for analyzing siRNA effects has to be determined empirically by testing a range of incubation time. The time can vary from 24 to 96 hrs depending on the cells used and the experimental targets tested.
- f. **Transfection efficiency:** High transfection efficiency is essential for achieving siRNA effect using a transient transfection approach. GFP plasmid can be used as a transfection efficiency control.

A protocol based on LipofectamineTM 2000 from Invitrogen for 12-well plates

1. Purchase LipofectamineTM 2000 reagent (Cat#11668-027) from Invitrogen
2. Plate the cells the day before transfection so that they are 90-95% confluent on the day of transfection. At the time of plating cells and diluting transfection reagents, avoid antibiotics - this helps cell growth and allows transfection without rinsing the cells. The cell density of 90-95% is very important. If the cell density is less than 90%, transfection may have toxicity on the cells.
3. Dilute vector-based siRNA plasmid with 100 μl of Opti-MEM (Cat# 31985062) from Invitrogen and mix gently.
4. Dilute LipofectamineTM 2000 Reagent into 100 μl of Opti-MEM medium in a second tube; mix gently and incubate at room temperature for 5 min.
5. Combine diluted DNA (from Step 3) and diluted LipofectamineTM 2000 Reagent (from step 4); mix and incubate at RT for 20 min.
6. Add 200 μl of DNA-LipofectamineTM 2000 Reagent complexes to each well. Mix gently by rocking the plate back and forth.
7. Perform assays on the cells 24-48 h after the start of transfection. It is not necessary to remove the complexes or change the medium; however, growth medium may be replaced after 4-6 hours without loss of transfection activity.
8. Optimizing transfection: The suggested starting points are listed in Table 1. To obtain the highest transfection efficiency and low non-specific effects, optimize transfection conditions by varying DNA and



Lipofectamine™ 2000 concentrations, and cell density. Make sure that cells are greater than 90% confluent and vary DNA (µg): Lipofectamine™ 2000 (µl) ratios from 1:0.5 to 1:5.

Table I. Suggested starting amounts of reagents for transfection in different culture vessels:

Culture vessel	Surface Area per Well (cm ²)	Relative Surface Area (vs. 24-well)	Volume of Plating Medium	DNA (µg) and Dilution Volume (µl)	Lipofectamine™ 2000 (µl)
96 well	0.3	0.2	100 µl	0.2 µg in 25 µl	0.5 µl in 25 µl
24 well	2	1	500 µl	0.8 µg in 50 µl	2.0 µl in 50 µl
12 well	4	2	1 ml	1.6 µg in 100 µl	4.0 µl in 100 µl
6 well	10	5	2 ml	4.0 µg in 250 µl	10 µl in 250 µl
35 mm	10	5	2 ml	4.0 µg in 250 µl	10 µl in 250 µl
60 mm	20	10	5 ml	8.0 µg in 0.5 ml	20 µl in 0.5 ml
100 mm	60	30	15 ml	24 µg in 1.5 ml	60 µl in 1.5 ml

A brief protocol for siFLuc construct transfection (Figure 1).

1. To use siFLuc constructs (Cat. SD1531, or SD1532), pGL-3 control vector (Promega, Cat. #E1741) and pRL-TK vector (Promega, Cat. #E2241) need to be purchased from Promega.
2. To observe the effect of siFLuc, three sets of transfections are needed: a. pGL-control and pRL-TK vector alone; b. pGL-3 control, pRL-TK, and siFLuc vector; c. pGL-3 control, pRL-TK, and an empty pRNA vector.
3. For cell transfection, 12-well plates can be used. For 293-F Cells SFM adapted (Cat.# 11625-019) from Invitrogen, 200,000 cell can be seeded the day before transfection.
4. The amount of siFLuc plasmid used for transfection should be 10-30 fold higher than that of pGL-3 control plasmid. For 293-F, 0.16 µg of pGL-3 control and 0.16 µg pRL-TK vector were used, 1.6 µg of siLuc construct or empty vector are used for each well.
5. The plasmid can be transfected into mammalian cells using Lipofectamine™-2000 following the protocol.
6. The Firefly and Renilla luciferase activities can be measured using Dual Luciferase assay kit from Promega (Cat. #E1910) after 24 hrs of transfection.
7. The activities of Firefly luciferase need to be normalized using Renilla luciferase activity.
8. Typical inhibition of Firefly luciferase by siFLuc construct is about 80% (See Figure 1).

VII. Selecting antibiotic-resistant transfected cells

There are two major benefits for selecting antibiotic-resistant transfected cells:

1. For cells which are very difficult to be transfected or have very low transfection efficiency, using antibiotic selection will kill the cells that were not transfected with the siRNA expression vector. This will be able to reduce the background when analyzing the knockdown effect of siRNA.
2. By using the antibiotic selection, a stable cell line can be established. The stable cell line can be maintained and assessed for reduction of target gene expression for a long-term period.

pRNA series vectors have three kinds of antibiotics resistant genes: neomycin, hygromycin, and puromycin. Depending on your need, you can choose the appropriate resistant marker for establishing the stable cell line. The following are general procedures for selecting antibiotic-resistant cells.

1. Before doing antibiotic-resistant selection, perform a transient assay to check the effects of your siRNA constructs.
2. Following the transfection procedures as outlined in Section V to perform the cell transfection.
3. After 24 hours of transfection, lift the cells from plates using Trypsin-EDTA. Then add G-418, hygromycin, or puromycin to the medium for selection.
4. The concentration for G-418, hygromycin, or puromycin can be optimized from the range 50-1500 µg/ml. 100 µg/ml will be a good start point.



5. Examine the dishes for viable cells every 2 days. Identify the lowest G-418, hygromycin, or zeocin concentration that begins to give massive cell death for wild-type cells in approximately 7-9 days, and kills all wild-type cells within 2 weeks. Using this concentration to select cells containing pRNA plasmid after selection.
6. You can select a mixture of resistant cells or single colony depending on your need.
7. If the target gene is essential for cell survival, a stable cell line may not be obtained.

VIII. References

1. Elbashir SM, Harborth J, Lendeckel W, Yalcin A, Weber K, Tuschl T. (2001) Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. *Nature* 411: 494-498.
2. Yu JY, DeRuijter SL, Turner DL. (2002) RNA interference by expression of short-interfering RNAs and hairpin RNAs in mammalian cells. *Proc Natl Acad Sci U S A*. 99(9):6047-6052.
3. Brummelkamp, T.R., Bernards, R., and Agami, R. (2002) A system for stable expression of short interfering RNAs in mammalian cells. *Science* 296: 550-553.
4. Jacque, J.-M., Triques, K., and Stevenson, M. (2002) Modulation of HIV-1 replication by RNA interference. *Nature* 418: 435-438.
5. Sui, G., Soohoo, C., Affar, E.B., Gay, F., Shi, Y., Forrester, W.C., and Shi, Y. (2002) A DNA vector-based RNAi technology to suppress gene expression in mammalian cells. *Proc. Natl. Acad. Sci. USA* 99(8): 5515-5520.
6. Shen C, Buck AK, Liu X, Winkler M, and Reske SN. (2003) Gene silencing by adenovirus-delivered siRNA. *FEBS Lett* 539(1-3):111-114.
7. Barton GM, and Medzhitov R. (2002) Retroviral delivery of small interfering RNA into primary cells. *Proc Natl Acad Sci U S A* 99(23):14943-14945.
8. Kunach T, Gish G, Lickert H, Jones N, Pawson T, and Rossant J. (2003) Transgenic RNA interference in ES cell-derived embryos recapitulates a genetic null phenotype. *Nature Biotechnology* 21:559-561.
9. Czauderna F, Santel A, Hinz M, Fechtner M, Durieux B, Fisch G, Leenders F, Arnold W, Giese K, Klippel A, Kaufmann J. (2003) Inducible shRNA expression for application in a prostate cancer mouse model. *Nucleic Acids Res*. Nov 1;31(21):e127
10. Matsukura S, Jones PA, Takai D. (2003) Establishment of conditional vectors for hairpin siRNA knockdowns. *Nucleic Acids Res*. Aug 1;31(15):e77
11. van de Wetering M, Oving I, Muncan V, Pon Fong MT, Brantjes H, van Leenen D, Holstege FC, Brummelkamp TR, Agami R, Clevers H. (2003) Specific inhibition of gene expression using a stably integrated, inducible small-interfering-RNA vector. *EMBO Rep*. Jun;4(6):609-15.

Limited Use Label License

This product is the subject of the following patents: U.S. Patent No. 6,573,099 and foreign counterparts co-owned by Benitec Australia Ltd. Not-for-profit and academic entities who purchase this product receive the non-transferable right to use the product and its components in non-Commercial Purpose internal research.

All commercial and for-profit purchasers using this product for a Commercial Purpose are required to execute a commercial research license with Benitec by contacting Benitec at licensing@benitec.com. Entities wishing to use ddRNAi as a therapeutic agent or as a method to treat/prevent human disease also should contact Benitec at licensing@benitec.com.

Commercial Purpose means any activity by a party for tangible consideration and may include, but is not limited to, (i) use of the product in manufacturing; (ii) use of the product to provide services, information or data for a compensatory fee; (iii) use of the product for therapeutic, diagnostic or prophylactic purposes; (iv) use of the product in drug discovery or target validation and/or (v) resale of the product or its components whether or not the product is resold for use in research.



If purchaser is not willing to accept the limitations of this label license, seller is willing to accept the return of the product with a full refund. For terms and additional information relating to a commercial research license, or for licensing for any human therapeutic purpose, contact Benitec by email at licensing@benitec.com.

* Limited Use Label License: The use of CMV promoter is covered under U. S. Patent No. 5,168,062 and 5,385,839 owned and licensed by the University of Iowa Research Foundation and is sold for research use only. Commercial users must obtain a license to these patents directly from the University of Iowa Research Foundation (UIRF), 214 Technology Innovation Center, Iowa City, Iowa 52242. For further information, please contact the Associate Director of UIRF, at 319-335-4546.

GenScript Corporation

120 Centennial Ave., Piscataway, NJ 08854

Tel: 732-885-9188

Fax: 732-210-0262, 732-885-5878

Email: info@genscript.com

Web: <http://www.Genscript.com>